PDL BIOPHARMA, INC. Contracts & Agreements

Description of Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 29, 2021)

Capital Provision Agreement dated as of December 11, 2020 between the Company and Epps Investments LLC (Filed With SEC on March 29, 2021)

Settlement and Mutual Release Agreement among the Company, Samuel J. Wohlstadter, Nadine H. Wohlstadter, Hyperion Catalysis International, Wellstat Vaccines, LLC, Wellstat Immuno... (Filed With SEC on November 13, 2020)

Asset Transfer Agreement dated as of August 11, 2020 between Defined Diagnostics, LLC (F/K/A Wellstat Diagnostics LLC) and the (Filed With SEC on November 13, 2020)

Commercial Sublease Agreement dated as of November 5, 2020 by and between RDH Investments LLC and the Company (Filed With SEC on November 13, 2020)

Separation and Distribution Agreement, dated as of September 30, 2020, by and between PDL BioPharma, Inc (Filed With SEC on October 2, 2020)

Transition Services Agreement, dated as of September 30, 2020, between PDL BioPharma, Inc. and LENSAR, Inc (Filed With SEC on October 2, 2020)

Tax Matters Agreement, dated as of September 30, 2020, between PDL BioPharma, Inc. and LENSAR, Inc (Filed With SEC on October 2, 2020)

Confidential Severance Agreement and Release of All Claims (Filed With SEC on August 20, 2020)

Share Purchase Agreement between Bartleby Limited and the Company, dated as of July 30, 2020 (Filed With SEC on August 10, 2020)

2020 Annual Bonus Plan (Filed With SEC on May 11, 2020)

Description of Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 11, 2020)

Fifth Amendment to Lease Agreement between Mountain Bluebird Investments, LLC and the Company, effective November 11, 2019 (Filed With SEC on March 11, 2020)

Severance Plan adopted as of November 15, 2019 (Filed With SEC on March 11, 2020)

Form of Restricted Stock Agreement (Amended 11/15/19) (Filed With SEC on March 11, 2020)

Form of Restricted Stock Agreement Amendment Acknowledgment (Filed With SEC on March 11, 2020)

Form of Stock Option Agreement (Amended 11/15/19) (Filed With SEC on March 11, 2020)

Form of Stock Option Agreement Amendment Acknowledgment (Filed With SEC on March 11, 2020)

Form of Stock Option Grant Notice Supplement (Filed With SEC on March 11, 2020)

Form of Nonstatutory Inducement Stock Option Agreement (Amended 11/15/19) (Filed With SEC on March 11, 2020)

Form of Nonstatutory Inducement Stock Option Grant Notice Supplement (Filed With SEC on March 11, 2020)

Form of Inducement Restricted Stock Agreement (Amended 11/15/19) (Filed With SEC on March 11, 2020)

Wind Down Retention Plan effective as of December 21, 2019 (Filed With SEC on March 11, 2020)

Cooperation and Support Agreement, dated as of February 27, 2020, by and among PDL BioPharma, Inc., Engine Capital, L.P. and its affiliates (Filed With SEC on February 28, 2020)

Indenture, dated September 17, 2019, between PDL, BioPharma, Inc., as Issuer and The Bank of New York Mellon Trust Company, N.A., as Trustee (Filed With SEC on September 17, 2019)

Supplemental Indenture, dated September 17, 2019 by and between PDL BioPharma, Inc., as Issuer and The Bank of New York Mellon Trust Company, N.A., as Trustee (Filed With SEC on September 17, 2019)

Form of Exchange Agreement (Filed With SEC on September 13, 2019)

Confidential Severance Agreement and Release of All Claims (Filed With SEC on August 19, 2019)

Noden Settlement Letter and Supply Agreement Amendment (Filed With SEC on August 7, 2019)

Offer Letter between the Company and Ed Imbrogno (Filed With SEC on June 24, 2019)

2019 Annual Bonus Plan (Filed With SEC on May 9, 2019)

Securities Purchase Agreement (Filed With SEC on April 11, 2019)

Executive Severance Plan and Schedule of Benefits (Filed With SEC on April 10, 2019)

Form of Director and Officer Indemnification Agreement (Filed With SEC on November 7, 2018)

2018 Annual Bonus Plan (Filed With SEC on August 9, 2018)

Amendment No. 1 to Royalty Purchase and Sale Agreement and Bill of Sale between PDL Investment Holding, LLC and Depomed, Inc. and Depo DR Sub, LLC, dated August 2, 2018 (Filed With SEC on August 9, 2018)

Fourth Amendment to Lease Agreement between 932936, LLC and the Company, effective December 1, 2017 (Filed With SEC on March 16, 2018)

Confidential Separation Agreement and Release of All Claims between Danny Hart and the Company, dated as of October 23, 2017 (Filed With SEC on November 13, 2017)

Offer Letter between the Company and Dominique Monnet, executed August 31, 2017 (Filed With SEC on September 11, 2017)

2017 Annual Bonus Plan (Filed With SEC on May 3, 2017)

2017/21 Long-Term Incentive Plan (Filed With SEC on May 3, 2017)

Third Amendment to Lease Agreement between 932936, LLC and the Company, effective May 27, 2014 (Filed With SEC on May 3, 2017)

Schedule of Amendment to Omitted Credit Agreements (Filed With SEC on March 1, 2017)

PDL BIOPHARMA, INC. Debt Securities Indenture Dated as of November 22, 2016 The Bank of New York Mellon Trust Company, N.A., as Trustee CROSS-REFERENCE TABLE This Cross-Reference... (Filed With SEC on November 28, 2016)

PDL BIOPHARMA, INC. as Issuer AND THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. as Trustee SUPPLEMENTAL INDENTURE Dated as of November22, 2016 2.75% Convertible Senior Notes due... (Filed With SEC on November 28, 2016)

PDL BIOPHARMA, INC. 2.75% Convertible Senior Note due 2021 (Filed With SEC on November 28, 2016)

PDL BIOPHARMA, INC. (a Delaware corporation) $150,000,000 2.75% Convertible Senior Notes Due 2021 UNDERWRITING AGREEMENT Dated: November 16, 2016 PDL BIOPHARMA, INC. (a Delaware... (Filed With SEC on November 22, 2016)

Schedule of Amendment to Omitted Credit Agreement (Filed With SEC on August 4, 2016)

Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked * * * and has been filed separately with the Securities and Exchange Commission pursuant... (Filed With SEC on August 4, 2016)

_____________________________________ SUPPLY AGREEMENT (Tekturna, Rasilez) between NOVARTIS PHARMA AG AND NODEN PHARMA DAC... (Filed With SEC on August 4, 2016)

Noden Pharma DAC Investment and Stockholders Agreement (Filed With SEC on August 4, 2016)

ASSET PURCHASE AGREEMENT (Tekturna, Rasilez) between NOVARTIS AG, NOVARTIS PHARMA AG, SPEEDEL HOLDING AG, AND NODEN PHARMA DAC... (Filed With SEC on August 3, 2016)

PDL BIOPHARMA, INC. 2016 Annual Bonus Plan (Filed With SEC on May 4, 2016)

PDL BIOPHARMA, INC. Amended and Restated 2016/20 Long-Term Incentive Plan (Filed With SEC on May 4, 2016)

Schedule of Amendment to Omitted Credit Agreements (Filed With SEC on February 23, 2016)

PDL BIOPHARMA, INC. Amended and Restated 2015 Annual Bonus Plan (Filed With SEC on November 4, 2015)

PDL BIOPHARMA, INC. Amended and Restated 2015/19 Long-Term Incentive Plan (Filed With SEC on November 4, 2015)

Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked * * * and has been filed separately with the Securities and Exchange Commission pursuant... (Filed With SEC on November 4, 2015)

932 Southwood BoulevardIncline Village, NV 89451Phone: (775) 832-8500Fax: (775) 832-8502 (Filed With SEC on August 5, 2015)

SECOND AMENDMENT TO OFFICE LEASE (Filed With SEC on August 5, 2015)

PDL BIOPHARMA, INC. AMENDED AND RESTATED 2005 EQUITY INCENTIVE PLAN ORIGINALLY EFFECTIVE: JUNE 8, 2005 AMENDED EFFECTIVE: JUNE 20, 2007 AND JUNE 4, 2009 AMENDMENT AND RESTATEMENT... (Filed With SEC on August 5, 2015)

PDL BIOPHARMA, INC. 2015 Annual Bonus Plan (Filed With SEC on May 6, 2015)

PDL BIOPHARMA, INC. 2015/19 Long-Term Incentive Plan (Filed With SEC on May 6, 2015)

SECOND AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (Filed With SEC on February 23, 2015)

THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (Filed With SEC on February 23, 2015)

EXCHANGE AGREEMENT (Unrestricted Stock) (Filed With SEC on February 23, 2015)

Schedule of Amendment to Omitted Credit Agreement (Filed With SEC on February 23, 2015)

NOTE PURCHASE AGREEMENT dated April 1, 2014 between ACCEL 300, LLC and THE PURCHASER NAMED HEREIN NOTES DUE JUNE 1, 2029 (Filed With SEC on August 18, 2014)

PDL BIOPHARMA, INC. 2014/18 Long-Term Incentive Plan (Filed With SEC on August 18, 2014)

FIRST AMENDMENT TO OFFICE LEASE (Filed With SEC on August 18, 2014)

FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (Filed With SEC on August 18, 2014)

PDL BIOPHARMA, INC. 2014 Annual Bonus Plan (Filed With SEC on May 12, 2014)

SECOND SUPPLEMENTAL INDENTURE dated as of February 28, 2014 among PDL BIOPHARMA, INC., as Issuer, and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee... (Filed With SEC on March 3, 2014)

Form of Credit Agreement (Filed With SEC on March 3, 2014)

ROYALTY PURCHASE AND SALE AGREEMENT dated as of October 18, 2013 between DEPOMED, INC., DEPO DR SUB, LLC, as Seller, and PDL BIOPHARMA, INC., as Purchaser (Filed With SEC on March 3, 2014)

PDL BIOPHARMA, INC. (a Delaware corporation) $260,870,000 4.00% ConvertibleSenior Notes Due 2018 UNDERWRITING AGREEMENT Dated: February 6, 2014 PDL BIOPHARMA, INC. (a Delaware... (Filed With SEC on February 12, 2014)

PDL BIOPHARMA, INC. Debt Securities Indenture Dated as of February 12, 2014 The Bank of New York Mellon Trust Company, N.A., as Trustee CROSS-REFERENCE TABLE This Cross-Reference... (Filed With SEC on February 12, 2014)

PDL BIOPHARMA, INC. asIssuer AND THEBANK OF NEW YORK MELLON TRUST COMPANY, N.A. as Trustee SUPPLEMENTAL INDENTURE Dated as of February 12, 2014 $300,000,000 4.00%... (Filed With SEC on February 12, 2014)

CREDIT AGREEMENT dated as of April 18, 2013 among AVINGER, INC. as the Borrower, PDL BIOPHARMA, INC., as the Lender, and PDL BIOPHARMA, INC., as the Agent (Filed With SEC on August 8, 2013)

PDL BIOPHARMA, INC. 2013 Annual Bonus Plan (Filed With SEC on May 9, 2013)

PDL BIOPHARMA, INC. 2014 Long-Term Incentive Plan (Filed With SEC on May 9, 2013)

CREDIT AGREEMENT (Filed With SEC on August 2, 2012)

OFFICE LEASE (Filed With SEC on May 3, 2012)

932 Southwood BoulevardIncline Village, NV89451Phone:(775) 832-8500Fax ###-###-#### (Filed With SEC on February 23, 2012)

PDL BIOPHARMA, INC. 2013 Long-Term Incentive Plan (Filed With SEC on February 23, 2012)

PDLBIOPHARMA, INC. 2012 Annual Bonus Plan (Filed With SEC on February 23, 2012)

EXCHANGE AGREEMENT (Filed With SEC on February 2, 2012)

PDL BIOPHARMA, INC. 2.875% SERIES 2012 CONVERTIBLE SENIOR NOTES DUE FEBRUARY 15,2015 INDENTURE DATEDAS OF JANUARY 5, 2012 THE BANK OF NEW YORK MELLON TRUST COMPANY, N. A. AS... (Filed With SEC on January 6, 2012)

Indenture between the Company and The Bank of New York Mellon Trust Company, N.A., dated May 16, 2011 (Filed With SEC on July 29, 2011)

2012 Long-Term Incentive Plan (Filed With SEC on July 29, 2011)

Form of Executive Officer Severance Agreement (Filed With SEC on May 26, 2011)

PDL BIOPHARMA, INC. (a Delaware corporation) $135,000,000 3.75% Convertible Senior Notes Due 2015 UNDERWRITING AGREEMENT Dated: May 10, 2011 PDL BIOPHARMA, INC. (a Delaware... (Filed With SEC on May 16, 2011)

PDL BIOPHARMA, INC. as Issuer AND THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. as Trustee SUPPLEMENTAL INDENTURE Dated as of May 16, 2011 $155,250,000 3.75% Convertible Senior... (Filed With SEC on May 16, 2011)

Offer Letter between the Company and Danny Hart, dated January 11, 2010 (Filed With SEC on April 18, 2011)

PDLBIOPHARMA,INC. 2011Annual Bonus Plan (Filed With SEC on January 26, 2011)

PATENTLICENSE AGREEMENT between PROTEINDESIGN LABS, INC. and MEDIMMUNE,INC. (Filed With SEC on January 24, 2011)

PDL BIOPHARMA, INC. 2.875% CONVERTIBLE SENIOR NOTES DUE FEBRUARY 15, 2015 INDENTURE DATEDAS OF NOVEMBER 1, 2010 THE BANK OF NEW YORK MELLON TRUST COMPANY, N. A. AS TRUSTEE TABLE... (Filed With SEC on November 9, 2010)

SETTLEMENT AGREEMENT (Filed With SEC on November 9, 2010)

AMENDED AND RESTATED PATENT LICENSING MASTER AGREEMENT (QUEEN PATENTS) (Filed With SEC on November 9, 2010)

- 1 - (Filed With SEC on November 9, 2010)

PDLBIOPHARMA, INC. 2.875%CONVERTIBLE SENIOR NOTES DUE FEBRUARY15, 2015 INDENTURE DATED ASOF OCTOBER[], 2010 THE BANKOF NEW YORK MELLON TRUST COMPANY, N. A. ASTRUSTEE TABLEOF... (Filed With SEC on October 27, 2010)

EXCHANGEAGREEMENT (Filed With SEC on October 27, 2010)

PRIVATEPLACEMENT PURCHASE AGREEMENT (Filed With SEC on October 27, 2010)

EXCHANGEAND PURCHASE AGREEMENT (RestrictedConvertible Notes) (Filed With SEC on October 27, 2010)

EXCHANGEAGREEMENT (Filed With SEC on August 5, 2010)

PDL BIOPHARMA, INC. 2010 Annual Bonus Plan (Filed With SEC on April 19, 2010)

PDL BIOPHARMA, INC. 2005 EQUITYINCENTIVE PLAN (AMENDED AND RESTATEDEFFECTIVE JUNE 4, 2009) PDL BIOPHARMA, INC. (Filed With SEC on July 31, 2009)

AMENDMENT NO. 1 TO SEPARATION AND DISTRIBUTION AGREEMENT (Filed With SEC on March 2, 2009)

CONFIDENTIAL PROVISIONS MARKED EXHIBIT 10.26 (CONFIDENTIAL) AMENDMENT NO. 2 TO THE PATENT LICENSING MASTER AGREEMENT (Filed With SEC on March 2, 2009)

CONFIDENTIAL PROVISIONS MARKED (Filed With SEC on March 2, 2009)

AMENDMENT TO THE RIGHTS AGREEMENT (Filed With SEC on February 5, 2009)

Separation and Distribution Agreement between PDLBioPharma, Inc., a Delawarecorporation and FacetBiotech Corporation, a Delawarecorporation Dated as of December17, 2008 (Filed With SEC on December 23, 2008)

Transition Services Agreement PDL BioPharma, Inc., a Delaware corporation and Facet Biotech Corporation, a Delaware corporation Dated as of December 18, 2008 (Filed With SEC on December 23, 2008)

TaxSharing and Indemnification Agreement (Filed With SEC on December 23, 2008)

CONFIDENTIAL SEPARATION AGREEMENTAND GENERAL RELEASE (Filed With SEC on November 7, 2008)

CONFIDENTIALPROVISIONS REDACTED (Filed With SEC on November 7, 2008)

PDLBIOPHARMA, INC. RETENTIONAND SEVERANCE PLAN FOR CHIEFEXECUTIVE OFFICER (Filed With SEC on September 25, 2008)

ASSET PURCHASE AGREEMENT BY AND BETWEEN PDL BIOPHARMA, INC., (Filed With SEC on December 17, 2007)

FIRST AMENDMENT TO COLLABORATION AGREEMENT (Filed With SEC on November 7, 2007)

(2002 Outside Directors Stock Option Plan) (Filed With SEC on August 9, 2007)

(1999 Stock Option Plan) (Filed With SEC on August 9, 2007)

PDL BioPharma, Inc. 2005 Equity Incentive Plan (Filed With SEC on June 22, 2007)

PDL BioPharma, Inc. 2005 Equity Incentive Plan (Filed With SEC on May 10, 2007)

PDL BIOPHARMA, INC. AND MELLON INVESTOR SERVICES, LLC as Rights Agent RIGHTS AGREEMENT Dated as of August 25, 2006 TABLE OF CONTENTS (Filed With SEC on August 29, 2006)

PROTEIN DESIGN LABS, INC. 1999 STOCK OPTION PLAN (Filed With SEC on August 9, 2006)

PROTEIN DESIGN LABS, INC. 1999 NONSTATUTORY STOCK OPTION PLAN (Filed With SEC on August 9, 2006)

PDL BIOPHARMA, INC. STOCK OPTION AGREEMENT (INCENTIVE) (Filed With SEC on August 9, 2006)

PDL BIOPHARMA, INC. STOCK OPTION AGREEMENT (NONSTATUTORY) (Filed With SEC on August 9, 2006)

PDL BIOPHARMA, INC. NOTICE OF GRANT OF STOCK OPTION (Filed With SEC on August 9, 2006)

PDL BIOPHARMA, INC. STOCK OPTION AGREEMENT (Filed With SEC on August 9, 2006)

PDL BIOPHARMA, INC. NOTICEOF GRANT OF RESTRICTED STOCK AWARD (Filed With SEC on August 9, 2006)

PDL BIOPHARMA, INC. RESTRICTEDSTOCK AGREEMENT (Filed With SEC on August 9, 2006)

SUBLEASE (Filed With SEC on July 6, 2006)

TRIPLE NET SPACE LEASE between PACIFIC SHORES INVESTORS LLC, as (Filed With SEC on July 6, 2006)

Exhibit 10.54 to Form 10-K CONFIDENTIAL PROVISIONS REDACTED (Filed With SEC on March 16, 2006)

Exhibit 10.55 to Form 10-K CONFIDENTIAL PROVISIONS REDACTED (Filed With SEC on March 16, 2006)

AMENDED AND RESTATED CONSULTING AGREEMENT (Filed With SEC on March 16, 2006)

SYNTEX (U.S.A.) INC. - AMERICAN HOME PRODUCTS CORPORATION SUBLICENSE AND SUPPLY AGREEMENT DATED SEPTEMBER 1, 1993 RE: NICARDIPINE IV TABLE OF CONTENTS (Filed With SEC on May 10, 2005)

ASSETPURCHASE AGREEMENT CENTOCOR,INC (SELLER) ESPPHARMA, INC. (BUYER) January 31,2005 (Filed With SEC on March 25, 2005)

AMENDEDAND RESTATED WORLDWIDE AGREEMENT (Filed With SEC on March 16, 2005)

ICOS CORPORATION MANUFACTURING AGREEMENT (Filed With SEC on March 16, 2005)

PROTEINDESIGN LABS, INC. 2.00%CONVERTIBLE SENIOR NOTES DUE FEBRUARY 15, 2012 INDENTURE DATEDAS OF FEBRUARY 14, 2005 J.P.Morgan Trust Company, National Association, ASTRUSTEE (Filed With SEC on February 16, 2005)

Protein Design Labs, Inc. 2.00% Convertible Senior Notesdue 2012 RegistrationRights Agreement (Filed With SEC on February 16, 2005)

CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on November 5, 2004)

AMENDMENT NO. 1 TO SPECIAL COMPENSATION AND EMPLOYMENT AGREEMENT DATED MAY 1, 2002 BETWEEN LAURENCE JAY KORN AND PROTEIN DESIGNLABS, INC. (Filed With SEC on May 5, 2004)

CONFIDENTIALPROVISIONS MARKED (Filed With SEC on March 8, 2004)

EXHIBIT10.46 (CONFIDENTIAL) (Filed With SEC on March 8, 2004)

AMENDMENT NO. 1 TO THE HERCEPTINLICENSE AGREEMENT (Filed With SEC on March 8, 2004)

CONFIDENTIAL PROVISIONS MARKED EXHIBIT 10.48 (CONFIDENTIAL) (Filed With SEC on March 8, 2004)

CONFIDENTIAL PROVISIONS MARKED EXHIBIT 10.49 (CONFIDENTIAL) (Filed With SEC on March 8, 2004)

Protein Design Labs, Inc. Retiree Health Care Plan Effective June 1, 2003 (Filed With SEC on March 8, 2004)

Financial statements of businesses acquired (Filed With SEC on April 18, 2003)

Category

Industry

Companies

Contracts

PDL BIOPHARMA, INC. Contracts & Agreements